[ad_1]
Lu R-M, Hwang Y-C, Liu IJ, Lee C-C, Tsai H-Z, Li H-J, Wu H-C. Growth of therapeutic antibodies for the remedy of illnesses. J Biomed Sci. 2020;27:1.
Grilo AL, Mantalaris A. The more and more human and worthwhile monoclonal antibody market. Tendencies Biotechnol. 2019;37:9–16.
Berger M, Shankar V, Vafai A. Therapeutic purposes of monoclonal antibodies. Am J Med Sci. 2002;324:14–30.
Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Strategies. 2005;36:3–10.
Strohl W, Strohl L. 8-Monoclonal antibody targets and mechanisms of motion. Thera Antibody Eng. 2012;9:163–96.
Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM. Humanization of a mouse monoclonal antibody by CDR–grafting: the significance of framework residues on loop conformation. Protein Eng Des Sel. 1991;4:773–83.
Mateo C, Moreno E, Amour Okay, Lombardero J, Harris W. Humanization of a mouse monoclonal antibody that blocks the epidermal progress issue receptor: restoration of antagonistic exercise. Immunotechnology. 1997;3:71–81.
Harding FA, Stickler MM, Razo J, DuBridge R. The immunogenicity of humanized and absolutely human antibodies: residual immunogenicity resides within the CDR areas. MAbs. 2010;2(3):256–65.
Safdari Y, Farajnia S, Asgharzadeh M, Khalili M. Antibody humanization strategies – a evaluation and replace. Biotechnol Genet Eng Rev. 2013;29:175–86.
Khee Hwang WY, Almagro JC, Buss TN, Tan P, Foote J. Use of human germline genes in a CDR homology-based strategy to antibody humanization. Strategies. 2005;36:35–42.
Pelat T, Thullier P. Non-human primate immune libraries mixed with germline humanization. MAbs. 2009;1:377–81.
Tan P, Mitchell DA, Buss TN, Holmes MA, Anasetti C, Foote J. “Superhumanized” antibodies: discount of immunogenic potential by complementarity-determining area grafting with human germline sequences: Utility to an Anti-CD28. J Immunol. 2002;169:1119–25.
Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M-P, Thullier P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol. 2008;384:1400–7.
Sangpheak Okay, Waraho-zhmayev D, Haonoo Okay, Torpaiboon S, Teacharsripaiboon T, Rungrotmongkol T, Poo-arporn RP. Investigation of interactions between binding residues and solubility of grafted humanized anti-VEGF IgG antibodies expressed as full-length format within the cytoplasm of a novel engineered E coli SHuffle pressure. RSC Adv. 2021;11:6035–48.
Olimpieri PP, Marcatili P, Tramontano A. Tabhu: instruments for antibody humanization. Bioinformatics. 2015;31:434–5.
Bujotzek A, Lipsmeier F, Harris SF, Benz J, Kuglstatter A, Georges G. VH-VL orientation prediction for antibody humanization candidate choice: A case research. MAbs. 2016;8(2):288–305.
Zhao Z, Worthylake D, LeCour L Jr, Maresh GA, Pincus SH. Crystal Construction and Computational Modeling of the Fab Fragment from a Protecting Anti-Ricin Monoclonal Antibody. PLoS ONE. 2012;7:e52613.
Kurella VB, Gali R. Construction guided homology mannequin primarily based design and engineering of mouse antibodies for humanization. Bioinformation. 2014;10:180.
Teplyakov A, Luo J, Obmolova G, Malia TJ, Candy R, Stanfield RL, Kodangattil S, Almagro JC, Gilliland GL. Antibody modeling evaluation II. Buildings and fashions Proteins. 2014;82:1563–82.
Maier JK, Labute P. Evaluation of absolutely automated antibody homology modeling protocols in molecular working atmosphere. Proteins. 2014;82:1599–610.
Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico choice of therapeutic antibodies for growth: Viscosity, clearance, and chemical stability. Proc Natl Acad Sci. 2014;111:18601–6.
Kortkhonjia E, Brandman R, Zhou JZ, Voelz VA, Chorny I, Kabakoff B, Patapoff TW, Dill KA, Swartz TE. Probing antibody inner dynamics with fluorescence anisotropy and molecular dynamics simulations. MAbs. 2013;5:306–22.
Margreitter C, Mayrhofer P, Kunert R, Oostenbrink C. Antibody humanization by molecular dynamics simulations—in-silico guided choice of crucial backmutations. J Mol Recognit. 2016;29:266–75.
Wall ME, Phillips GN Jr, Subramaniam S. Protein construction dedication utilizing a database of interatomic distance chances. Protein Sci. 1999;8:2720–7.
Maiorov VN, Crippen GM. Significance of root-mean-square deviation in evaluating three-dimensional constructions of globular proteins. J Mol Biol. 1994;235:625–34.
Carugo O. Statistical validation of the root-mean-square-distance, a measure of protein structural proximity. Protein Eng Des Sel. 2007;20:33–7.
Sargsyan Okay. How molecular measurement impacts RMSD purposes in molecular dynamics simulations. J Chem Concept Comput. 2017;13:1518–24.
Damm KL, Carlson HA. Gaussian-weighted RMSD superposition of proteins: a structural comparability for versatile proteins and predicted protein constructions. Biophys J. 2006;90:4558–73.
Presta LG, Chen H, O’connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial progress issue monoclonal antibody for the remedy of strong tumors and different problems. Can Res. 1997;57:4593–9.
Zhang Y-F, Ho M. Humanization of high-affinity antibodies focusing on glypican-3 in hepatocellular carcinoma. Sci Rep. 2016;6:1–11.
Hanf KJ, Arndt JW, Chen LL, Jarpe M, Boriack-Sjodin PA, Li Y, van Vlijmen HW, Pepinsky RB, Simon KJ, Lugovskoy A. Antibody humanization by redesign of complementarity-determining area residues proximate to the acceptor framework. Strategies. 2014;65:68–76.
Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable area sequence evaluation instrument. Nucleic Acids Res. 2013;41:W34–40.
Ducancel F, Muller BH. Molecular engineering of antibodies for therapeutic and diagnostic functions. MAbs. 2012;4:445–57.
Lonberg N. Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol. 2008;181(181):69–97.
Tyagi P. Current outcomes and ongoing trials with panitumumab (ABX-EGF), a completely human anti-epidermal progress issue receptor antibody, in metastatic colorectal most cancers. Clin Colorectal Most cancers. 2005;5:21–3.
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele Okay, Gu Y, Karakunnel JJ, Rizvi NA. Security and antitumour exercise of durvalumab plus tremelimumab in non-small cell lung most cancers: a multicentre, part 1b research. Lancet Oncol. 2016;17:299–308.
Leem J, Dunbar J, Georges G, Shi J, Deane CM. ABodyBuilder: Automated antibody construction prediction with knowledge–pushed accuracy estimation. MAbs. 2016;8(7):1259–68.
Yamashita Okay, Ikeda Okay, Amada Okay, Liang S, Tsuchiya Y, Nakamura H, Shirai H, Standley DM. Kotai Antibody Builder: automated high-resolution structural modeling of antibodies. Bioinformatics. 2014;30:3279–80.
Fernández-Quintero ML, Heiss MC, Liedl KR. Antibody humanization—the Affect of the antibody framework on the CDR-H3 loop ensemble in answer. Protein Eng Des Sel. 2019;32:411–22.
Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH. Ofatumumab monoclonal antibody affinity maturation by in silico modeling. Iran Biomed J. 2018;22(3):180–92.
Pantazes RJ, Maranas CD. MAPs: a database of modular antibody components for predicting tertiary constructions and designing affinity matured antibodies. BMC Bioinformatics. 2013;14:168.
Fernández-Quintero ML, Loeffler JR, Bacher LM, Waibl F, Seidler CA, Liedl KR. Native and world rigidification upon antibody affinity maturation. Entrance Mol Biosci. 2020;7:182.
Padlan EA. Anatomy of the antibody molecule. Mol Immunol. 1994;31:169–217.
Regep C, Georges G, Shi J, Popovic B, Deane CM. The H3 loop of antibodies exhibits distinctive structural traits. Proteins. 2017;85:1311–8.
Liang S, Dai J, Hou S, Su L, Zhang D, Guo H, Hu S, Wang H, Rao Z, Guo Y. Structural foundation for treating tumor necrosis issue α (TNFα)-associated illnesses with the therapeutic antibody infliximab. J Biol Chem. 2013;288:13799–807.
Cavalli A, Camilloni C, Vendruscolo M. Molecular dynamics simulations with replica-averaged structural restraints generate structural ensembles in keeping with the utmost entropy precept. J Chem Phys. 2013;138:094112.
Case DA, Aktulga HM, Belfon Okay, Ben-Shalom IY, Brozell SR, Cerutti DS, Cheatham TE, Cisneros GA, Cruzeiro VWD, Darden TA, Duke RE, Giambasu G, Gilson MK, Gohlke H, Goetz AW, Harris R, Izadi S, Izmailov SA, Jin C, Kasavajhala Okay, Kaymak MC, King E, Kovalenko A, Kurtzman T, Lee TS, LeGrand S, Li P, Lin C, Liu J, Luchko T, Luo R, Machado M, Man V, Manathunga M, Merz KM, Miao Y, Mikhailovskii O, Monard G, Nguyen H, O’Hearn KA, Onufriev A, Pan F, Pantano S, Qi R, Rahnamoun A, Roe DR, Roitberg A, Sagui C, Schott-Verdugo S, Shen J, Simmerling CL, Skrynnikov NR, Smith J, Swails J, Walker RC, Wang J, Wei H, Wolf RM, Wu X, Xue Y, York DM, Zhao S, Kollman PA. Amber. San Francisco: College of California; 2021.
Onufriev A, Bashford D, Case DA. Exploring protein native states and large-scale conformational adjustments with a modified generalized born mannequin. Proteins. 2004;55:383–94.
Mitternacht S. FreeSASA: An open supply C library for solvent accessible floor space calculations. Analysis. 2016;5:1000.
[ad_2]
